Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four- and six-month-old infants
- 1 September 1997
- journal article
- clinical trial
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 16 (9) , 863-870
- https://doi.org/10.1097/00006454-199709000-00009
Abstract
The safety and immunogenicity of a diphtheria-tetanus toxoid-acellular pertussis vaccine (DTaP; Trepedia®)/Haemophilus influenzae b polysaccharide (PRP-T; ActHib®) combined vaccine (TriHibir®; Pasteur Mérieux Connaught) was compared with DTaP and PRP-T given at the same visit but at separate sites in a prospective multicenter, open label trial. Infants were randomized to four groups (three consistency lots of DTaP/PRP-T vs. one of the consistency lots given as separate vaccines); injections were administered at 2, 4 and 6 months of age. Pre-Dose 1 and post-Dose 3 sera were assayed for antibody titers against all antigens. Reactions to the vaccinations were assessed by parent questionnaire for 30 days after each injection visit. Four hundred eighty-five infants were enrolled; 296 evaluable infants were included in the DTaP/PRP-T group compared with 70 infants in the DTaP and PRP-T vaccine group. Infants who received the combined vaccine had higher post-Dose 3 geometric mean antibody titers to diphtheria antitoxin (P < 0.01) and pertussis filamentous hemagglutinin (P < 0.05) and lower geometric mean antibody titers to tetanus antitoxin (P < 0.05) and Haemophilus influenzae b (Hib) polysaccharide (PRP) (P < 0.05). The geometric mean anti-PRP antibody titer in the DTaP/PRP-T group was 4.3 μg/ml compared with 7.0 μg/ml in the separate vaccine group (P < 0.05), and the percentage of infants with antibody titers ≥0.15 and 1 μg/ml were, respectively, 95 and 86%, whereas they were 100% for both titers in the separate vaccines group. DTaP/PRP-T vaccine given concomitantly or 1 month apart from hepatitis B vaccine and oral poliomyelitis vaccine caused no significant differences in immunogenicity or safety. The safety assessments for the DTaP/PRP-T vaccine showed no consistent differences in systemic or local injection site reactions compared with DTaP and PRP-T administered separately. Although the antibody responses to tetanus and Hib polysaccharide in the evaluated DTaP/PRP-T combined vaccine were significantly lower than those seen after separate DTaP and PRP-T administration, the combined vaccine elicited an immune response against diphtheria, tetanus, pertussis and Haemophilus influenzae b likely to confer protection.Keywords
This publication has 32 references indexed in Scilit:
- Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b - PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccineEuropean Journal of Pediatrics, 1996
- EFFICACY OF THE COMBINED DIPHTHERIA-TETANUS TOXOIDS-PERTUSSIS-HAEMOPHILUS CONJUGATE VACCINEThe Pediatric Infectious Disease Journal, 1995
- Potential Alterations in Immunogenicity by Combining or Simultaneously Administering Vaccine ComponentsaAnnals of the New York Academy of Sciences, 1995
- Immunogenicity and safety of Haemophilus influenzae type b-tetanus protein conjugate vaccine alone or mixed with diphtheria-tetanus-pertussis vaccine in infantsThe Journal of Pediatrics, 1994
- Responses of children to booster immunization with their primary conjugate Haemophilus influenzae type B vaccine or with polyribosylribitol phosphate conjugated with diphtheria toxoidThe Journal of Pediatrics, 1993
- Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infantsThe Journal of Pediatrics, 1992
- Priming and induction of Haemophilus influenzae type b capsular antibodies in early infancy by Dpo20, an oligosaccharide-protein conjugate vaccineThe Journal of Pediatrics, 1987
- Prevention ofHaemophilus influenzaeType b Infections in High-Risk Infants Treated with Bacterial Polysaccharide Immune GlobulinNew England Journal of Medicine, 1987
- Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide—Neisseria meningitidis outer membrane protein conjugate vaccineThe Journal of Pediatrics, 1987
- Prevention ofHemophilus influenzaeType B Bacteremic Infections with the Capsular Polysaccharide VaccineNew England Journal of Medicine, 1984